Safety and Feasibility of Using CMV T Cell Immunity Test to Guide Antiviral Treatment After Lung Transplant

What this Trial Is About

Researchers are evaluating the safety and feasibility of using a laboratory test called the inSIGHT12 CMV T Cell Immunity Panel to guide how long lung transplant recipients take antiviral medication called valganciclovir. The test measures immune responses to cytomegalovirus CMV, a common viral infection. The goal is to safely reduce the duration of antiviral treatment after lung transplant based on the patients immune response. Participants receive the CMV T Cell Immunity Panel test every three months after their lung transplant. Those with a certain immune response level may stop taking valganciclovir earlier than the standard 12 months. Valganciclovir is given daily starting the first day after transplant at a standard dose, with adjustments as needed for kidney function or side effects. Additional tests like donor-derived cell-free DNA assays are also used to monitor the transplant. During the study, participants will be closely monitored for CMV viremia-free survival over the first year after transplant, along with occurrences of CMV viremia, treatment-resistant CMV, and other infections such as bacterial pneumonia and Aspergillus. Researchers will track blood tests, immune function, and infection status to evaluate safety and effectiveness. The study is sponsored by NYU Langone Health and will continue until May 2028.

CMV Immunity Monitoring in Lung Transplant Recipients